Experimental cancer drug TNG908 tested in patients with rare gene deletion
Disease control
Terminated
This study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results a…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC